Alnylam Canada Signs LOI From Pan-Canadian Pharmaceutical Alliance For The Public Reimbursement Of AMVUTTRA For The Treatment Of Hereditary Transthyretin-Mediated Amyloidosis In Adults
Alnylam Canada Signs LOI From Pan-Canadian Pharmaceutical Alliance For The Public Reimbursement Of AMVUTTRA For The Treatment Of Hereditary Transthyretin-Mediated Amyloidosis In Adults
One step closer to achieving public reimbursement of AMVUTTRA for hATTR patients in Canada
離在加拿大實現AMVUTTRA藥品對hATTR患者公共報銷更近了一步
MISSISSAUGA, ON, Oct. 18, 2024 /CNW/ - Alnylam Canada ULC is pleased to announce that it has signed a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for the public reimbursement of AMVUTTRA (vutrisiran injection), an RNAi therapeutic administered by quarterly subcutaneous injection, for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis).1 This comes following a positive recommendation from the Canadian Drug Agency (CDA) and the Institut national d'excellence en santé et services sociaux (INESSS), and signals the next step in the process where individual participating provinces and territories will start to list AMVUTTRA on their formularies.
MISSISSAUGA，安大略省，2024年10月18日/CNW/ - Alnylam Canada ULC很高興宣佈，已與全加拼採藥品同盟（pCPA）簽署了一份關於AMVUTTRA（vutrisiran注射劑）公共報銷的意向書（LOI），該藥品是一種RNAi療法，每季度皮下注射一次，用於治療具有遺傳性前轉甲狀腺素介導的澱粉樣蛋白聚合物病的成人患者的1期或2期多發性神經病。這是在加拿大藥品管理局（CDA）和衛生及社會服務卓越國家研究所（INESSS）提出積極意見後，並標誌着個別參與省份和地區開始將AMVUTTRA列入其處方目錄流程的下一步驟。
譯文內容由第三人軟體翻譯。
